R
adiotherapy plays a pivotal role in the treatment of solid tumors. Either alone or in combination with surgery, radiation can produce enduring locoregional control in a wide variety of cancers. Effectiveness depends on tumor-specific characteristics, as well as on irradiation modality, treatment plan and targeting accuracy. To date, photon therapy is the most common treatment modality, although in the past 30 years neutron therapy has become increasingly widespread, proving effective in the treatment of patients with prostate cancer, 1 head and neck squamous cell carcinoma, 2 carcinoma of the cervix, 3 soft tissue sarcoma 4 and locally advanced breast cancer. 5, 6 Neutrons present a number of radiobiological advantages over photons, such as efficacy against hypoxic cells, reduced cell cycle-related radioresistance and induction of less repairable DNA damage, the outcome of which is low oxygen enhancement ratio (OER) and high relative biological effectiveness (RBE). However, severe late complications have been reported for many tumor sites, partly relating to technical problems, such as less effective collimation, inadequate beam energies and shaping. 7 Experimental biological strategies hold potential to overcome limitations of dose delivery in radiotherapy. In particular, radiation can be exploited to selectively activate gene expression in the tumor mass. The combination of gene therapy strategies with radiotherapy may increase the effectiveness of each radiation dose fraction, resulting in a smaller total dose, reduced normal tissue damage and improved patient quality of life (for a recent review see Scott and Greco 8 ). Sophisticated beam delivery and collimator systems, such as those available at Wayne State University, Detroit, MI, 9 would allow precise targeting of gene therapy activation, even after neutron irradiation. To this end, the radiation-responsive promoter from the early growth response 1 (Egr1) gene has been extensively used for X-ray-driven radiogenetic therapy. [10] [11] [12] Recently, in a phase I clinical trial, an adenoviral vector containing the Egr1 gene promoter controlling the expression of the cytotoxin tumor necrosis factor a (Ad-Egr1-TNFa) has shown no increase in toxicity and some enhancement in tumor response, compared with radiation alone. 13 The mechanism of Egr1 activation after radiation and other cytotoxic agents is still unknown. However, radiation inducibility was pinpointed to 10 nucleotide motifs of consensus sequence CC(A/T) 6 GG, known as CArG elements, within the 490 nucleotide Egr1 promoter region.
14 Reactive oxygen species (ROS) have been recognized to be involved in CArG activation, since hydrogen peroxide could induce CArG-mediated transcription. 15 In an attempt to produce more responsive promoters and to eliminate binding sites for nonradiation-induced transcription factors, we have produced synthetic promoters containing tandem repeats of isolated CArG elements. 16 These new promoters demonstrated greater inducibility and lower basal activity than the wild-type Egr1 promoter in a number of human tumor cell types, 16, 17 and could efficiently control experimental suicide gene therapy after clinically significant doses of X-rays in vitro and in vivo. [16] [17] [18] [19] Gene therapy vectors containing CArG elements also have potential to be used in combination with chemotherapy, since the native Egr1 gene has been shown to be induced by cisplatin 20, 21 and the anthracycline antibiotic doxorubicin. 22 ''Chemogenetic'' therapy may represent a novel and promising avenue for combinational therapy, since the efficacy of these antineoplastic agents is often limited by normal tissue toxicity and tumor resistance. 23, 24 In the present work, we first investigated the response of synthetic promoters containing isolated CArG elements to clinically relevant doses of neutrons for experimental gene therapy. Second, the activation of such promoters in the presence of the chemotherapeutic drugs cisplatin and doxorubicin was evaluated. As transgenes, the green fluorescent protein (GFP) reporter gene and the herpes simplex virus thymidine kinase (HSVtk) suicide gene were used. The HSVtk/ganciclovir (GCV) combination is the most characterized suicide gene therapy strategy, and is currently used in a number of clinical trials for the treatment of solid tumors. 25 Furthermore, HSVtk/GCV treatment has been successfully combined with radiation 26, 27 and chemotherapy. 28, 29 Materials and methods
DNA plasmid constructs
Construction of the plasmids pE9GFP, pE9 ns2GFP, pCMVGFP, pE9tk, pE9 ns2tk and pCMVtk, based on the vector pCIneo (Promega, Madison, WI), has been described previously.
16-18
Cell culture and transfection
Human MCF-7 breast adenocarcinoma and U373-MG glioblastoma cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). Cells were maintained in monolayer culture in complete RPMI medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin (Sigma Aldrich, St. Louis, MO), 2 mM L-glutamine (Invitrogen), and incubated in a humidified incubator at 371C in 5% O 2 :5% CO 2 :90% N 2 . Cells were routinely tested and found free of mycoplasma infection (PCR Mycoplasma Detection Set, Takara Bio Inc., Otsu, Japan). Transient transfections with the GFP-constructs were carried out by using Lipofectamine (Invitrogen), as described previously. 16 Transient transfections with the HSVtk-constructs were performed using TransIT (Mirus Corporation, Madison, WI), according to manufacturer's instructions.
Irradiation procedure and drug exposure
At 2 days after transfection, the cells were exposed to Xrays by using a Pantak X-ray generator operated at 320 kVp, at a dose rate of 85.2 cGy/min. Neutron irradiation was conducted at the Gershenson Radiation Oncology Center (Harper Hospital, Detroit, MI) superconducting cyclotron, 30 at a dose rate of 55 cGy/min. The fast neutron facility produces a beam by accelerating 48.5 MeV deuterons onto a beryllium target. The neutron beam, with a maximum energy of 52.5 MeV and a mean energy of approximately 20 MeV, was shaped using a custom-made multirod tungsten collimator. 9 Alternatively, the cells were exposed to cisplatin [cisdiammine-dichloroplatinum (II)] or doxorubicin (adriamycin; both from Sigma) in culture. 
Analysis of gene expression

Cell growth inhibition assay
At 24 hours after transfection, cells were harvested, plated in 96-well plates 2000 (2000 cells/well; 8 wells/data point) and allowed to attach for 3-5 hours in the presence of 50 mM GCV (Sigma Aldrich). The cells were subsequently exposed to ionizing radiation or chemotherapeutic drugs as described above. Cells were grown until control plates reached 80% confluence (3-5 days) and assayed using the CellTiter 96 TM AQ ueous Assay (Promega) according to manufacturer's instructions. Briefly, the culture medium was supplemented with 3-(4,5-dimethylthiazol-2-yl)-5-(carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) and phenazine methosulfate (PMS), at the final concentrations of 166 mg/ml and 12.5 mM respectively, and left to react for 2 hours. The plates were agitated to ensure complete mixing and scanned on a multiplate reader (Microplate Autoreader; Bio-Tek Instruments, Winooski, VT) at 492 nm. Absorbance of wells containing media, MTS and PMS only was subtracted from all data points. Growth inhibition was calculated relative to sham-treated controls.
Statistical analysis
Significance tests were carried out on the data groups by using analysis of variance (ANOVA) followed by pairwise comparison between specific groups (Student's t-test).
Results
Radiation-activated. reporter gene expression and suicide gene therapy
In previous reports we have shown that synthetic promoters containing direct repeats of isolated CArG elements can be activated by photon irradiation. [16] [17] [18] In the current work, we tested the inducibility of CArGcontaining gene promoters by neutron irradiation. Human MCF-7 breast adenocarcinoma cells were transiently transfected with plasmid constructs containing the reporter GFP driven by nine consecutive CArG elements. Two CArG sequences were studied: the prototype sequence (E9; CCTTATTTGG) and a novel sequence (E9 ns2; CCATATAAGG), both previously shown to effectively respond to X-rays. 17 In the absence of radiation, GFP expression in cells transfected with the pE9GFP and pE9 ns2GFP constructs was 13-18 and 10-16% of the values observed with the strong constitutive cytomegalovirus immediate early promoter (CMV IE), respectively. When the cells were exposed to 1.3 Gy neutrons, a dose commonly adopted in the clinic, 4, 5, 31 GFP expression significantly increased in cells transfected with either CArG construct (P-values shown in Fig 1) . This promoter activation was not significantly different than that induced by the clinically relevant X-ray dose of 2 Gy, or even a 4 Gy X-ray dose (Po.01; Fig 1) . As expected, no induction was observed in cells transfected with the same plasmid vector containing the CMV IE promoter controlling GFP expression or an empty vector (data not shown). Similar results were obtained in human U373-MG glioblastoma cells (data not shown).
In order to increase the effectiveness of our gene therapy strategy and improve its tumor-targeting potential, we have also constructed chimeric promoters containing combinations of CArG elements and hypoxia-responsive elements (HREs), 19 as severe hypoxia is a unique characteristic of solid tumors. These promoters were shown to be activated by hypoxia, photon irradiation or combined stimuli, with the combination of HREs from the erythropoietin (Epo) gene and CArG elements (Epo/E9) proving the most responsive across treatment and cell types. 19 In the present study, neutron irradiation activated the Epo/E9 promoter to the levels observed with the CArG-only promoter in both cell lines, indicating that the presence of the HREs did not affect the response of the chimeric promoters to neutrons.
The combination of gene therapy with neutron therapy was tested for tumor cell killing in vitro, by using the suicide combination HSVtk/GCV. MCF-7 cells were transiently transfected with constructs containing the coding sequence for a mutant version of HSVtk, displaying higher affinity for GCV, 32, 33 replacing the GFP gene, and tumor cell kill was measured after promoter activation and incubation with the prodrug GCV. As shown in Figure 2 , both X-rays and neutrons activated the CArG promoters, leading to gene therapymediated killing in human tumor cells. Cells transfected with the pE9tk or the pE9 ns2tk plasmids, when incubated with the prodrug GCV and exposed to X-rays or neutrons, showed levels of cell kill that were significantly higher than those observed in the absence of trigger stimulus or in the GFP control group (Po.01). Most importantly, compared with radiation alone, a significant increase in cytotoxicity was observed by combining radiation and gene therapy (P-values are indicated in Fig 2) . For example, a clinical dose of 1.3 Gy neutrons caused an average of 49% growth inhibition in MCF-7 cells. This increased to 63% in irradiated pE9tk-and pE9 ns2tk-cells treated with GCV, even though only 15-20% of the cells were transfected (Fig 2a) . Similarly, a 2 Gy dose of X-rays induced a 29% growth inhibition, which in the presence of GCV increased to 39% and 48% in pE9tk-and pE9 ns2tk-cells, respectively (Fig 2b) . These values were at least as high as those obtained with the strong constitutive CMV IE promoter construct (pCMVtk). 
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In order to test the potential of combining CArGmediated gene therapy with chemotherapy, we tested the inducibility of the E9 and E9 ns2 promoters by using the antineoplastic drugs cisplatin and doxorubicin. MCF-7 cells were exposed for 48 hours to the chemotherapeutic agents and GFP expression analyzed by FACS. For each drug, two standard concentrations were tested: 5 and 50 mM cisplatin (Fig 3a) , 0.1 and 1 mM doxorubicin (Fig  3b) . Both agents induced CArG activation, with a dosedependent trend (Fig 3) . In particular, doxorubicin appeared very effective in inducing the E9 ns2 promoter, with a six-fold increase in GFP expression after 1 mM (Fig  3b) . No induction was observed in cells transfected with the same construct containing the CMV IE promoter controlling GFP or an empty vector (results not shown).
The therapeutic potential of chemoactivated suicide gene therapy was also assessed. MCF-7 cells transiently transfected with HSVtk-containing constructs (or the negative control with GFP instead of HSVtk) were exposed to cisplatin or doxorubicin, in the presence of absence of GCV. In these experiments (as in the ones shown in Fig 2) , in order to detect the cytotoxic effects induced, the cells were incubated with the chemotherapeutic agents and GCV for 6 days before being tested for viability. Thus, compared with the induction experiments described above, lower dose levels of drugs were studied: 0.5 and 5 mM cisplatin (Fig 4a) , 0.01 and 0.1 mM doxorubicin (Fig 4b) . Efficient and selective GCVmediated toxicity was observed when the CArG promoters controlled the expression of HSVtk after drug incubation (Fig 4) . For example, exposure to 0.5 mM cisplatin alone induced an average growth inhibition of 29% in MCF-7 cells. In the presence of GCV, this value increased significantly to 65 and 67% in cells transfected with the E9 and the E9 ns2 promoter constructs, respectively, driving the expression of HSVtk (Po.01; Fig 4a) . Similar results were observed when gene therapy was combined with doxorubicin treatment (Fig 4b) .
Interestingly, cisplatin also directly enhanced HSVtk/ GCV-mediated toxicity, since concomitant GCV and 
Activation of CArG promoters for gene therapy
O Greco et al 0.5 mM cisplatin treatment induced a 46% growth inhibition in pCMVtk-transfectants (promoter not induced). This was significantly higher than that observed after HSVtk/GCV treatment alone (26%; Po.01). However, at the higher, more toxic dose of cisplatin (5 mM) no evident interaction between cisplatin and activated GCV was observed (Fig 4a) . No significant enhancement of HSVtk/GCV toxicity was observed, at either dose of doxorubicin (Fig 4b) .
Discussion
In the past few decades, neutron therapy has become an increasingly common treatment modality for solid tumors, although characterized by some normal tissue damage. Analogously, the extensively used chemotherapeutic drugs cisplatin and doxorubicin have been found to cause some toxicity in normal tissue during the treatment of a number of malignancies, including breast cancer. Furthermore, these agents may lead to the development of primary and secondary drug resistance in tumor cells, thereby limiting their clinical success. 23, 24 There is therefore scope for targeted combinational therapies that can enhance the efficacy of these standard treatments while minimizing side effects. In the present work, synthetic promoters containing CArG elements from the Egr1 gene were found to be activated by neutron irradiation, cisplatin and doxorubicin, and to be able to control efficient experimental suicide gene therapy. From the data presented, it appears that the combination of CArG-activated HSVtk/GCV suicide gene therapy with standard therapeutic modalities can be an advantageous antitumor approach. A breast adenocarcinoma cell line was adopted, since the efficacy of neutron therapy and these chemotherapeutic agents in the treatment of breast cancer is limited by normal tissue toxicity and tumor resistance. 5, 6, 23, 24 Moreover, similar results were observed in a human glioblastoma cell line.
The human Egr1 gene encodes a zinc finger transcription factor, induced after cellular injury or stress, that in turn activates downstream genes involved in growth and differentiation. 34 CArG sequences are the genetic elements in the Egr1 promoter that control the response of this gene to radiation, as delineated in a series of deletion experiments.
14 The serum response factor is known to bind to CArG elements (also known as serum response elements) during mitogenic activation of Egr1, but whether specific transcription factors are also involved in the radiation response is yet unknown. It is also unclear whether the response may be due to an alteration of DNA conformation after cellular redox change, or if DNA damage per se is the initiating signal. However, in human glioma cells, it has been demonstrated that the radiationinducibility of Egr1 depends on a diffusible growth factor secreted by irradiated cells into the culture medium, which activates the extracellular signal-regulated protein kinase (ERK) pathway. 35 The most biologically relevant DNA damage induced by ionizing radiation is the formation of double strand breaks (DSBs). It has been generally found, with some exceptions, that photons and neutrons induce DSBs with similar efficiency but that the neutron RBE for DSB formation is lower than the one for cell killing (reviewed by Britten et al. 36 ). However, clustered, less-repairable DSBs, often associated with other types of DNA damage such as base damage and DNA-protein crosslinks, appear to be generated after radiation of high linear energy transfer (LET), such as neutrons. 37, 38 Differences in the response to photons and neutrons have been observed in a number of cell types, in particular in the activation of early response genes. 39, 40 The c-fos, c-jun and protein kinase C (PKC) genes, for example, were induced by photons, but not by fission neutrons. 41, 42 Furthermore, differences have been noticed in the activation of the repair pathways in response to radiations of different LET, with the DNA-PK pathway, for example, being most relevant in the repair of DSBs induced by ionizing radiation of LET up to 100 keV/mm. 43 On the other hand, a-tubulin, g-actin and interleukin 1 were similarly induced both by g-rays and neutrons. 44, 45 In the present study, both neutron and photon irradiation activated CArGregulated gene expression (Figs 1 and 2) . However, the higher cytotoxic efficacy of neutrons was not reflected in Activation of CArG promoters for gene therapy O Greco et al stronger promoter activation. For example, 1.3 Gy neutrons induced a 49% cell growth inhibition that was statistically higher than that observed after cell irradiation with 2 Gy photons (29%; Po.01). On the other hand, there was no statistical difference in the induction of the CArG promoters by these neutron and photon doses (Fig  1) . This indicates that there may be some differences in the activation pathways of CArG elements by radiations of different qualities. Further experiments will be needed to elucidate these mechanisms.
The Egr1 promoter has also been reported to be activated by some antineoplastic drugs, such as doxorubicin and cisplatin. Transgenic mice with hypertrophied hearts treated with 10-30 mg/kg doxorubicin exhibited a three-to four-fold increase in Egr1 expression in ventricular cardiomyocytes 7 days after injection. 22 Interestingly, rodent cardiomyocytes and cardiac fibroblasts treated in vitro with 2 mM doxorubicin for 24 hours showed a significant decrease in Egr1 expression, compared with saline-treated cells. 22 In human HEK293 embryonic kidney cells, a 48 hours incubation with cisplatin caused a dose-dependent increase in activity of the Egr1 promoter, with an eight-fold peak at B67 mM. 21 Similarly, in human Seg-1 esophageal adenocarcinoma cells, exposure to 5 mM cisplatin for 24, 48 and 72 hours induced 3.3-, 5.3-and 3.5-fold increase in the activity of the Egr1 promoter, respectively. 20 In rat PROb colon adenocarcinoma cells, the above-mentioned incubation intervals resulted in induction levels of 2.9-, 1.9-and 1.6-fold. 20 Interestingly, the cisplatin-induced Egr1 promoter activation was found to be restricted to the region containing CArG elements. 20 Finally, infection of tumor xenografts established from both Seg-1 and PROb cells with the Ad-Egr1-TNFa adenovirus followed by 3 mg/kg cisplatin induced significant growth delay, compared with virus treatment or cisplatin alone. 20 The activation mechanism of the Egr1 gene in response to these cytotoxic drugs is still unclear. Cisplatin induces the formation of DNA-DNA crosslinks, inhibiting DNA replication and chain elongation. 46 The anthracycline antibiotic doxorubicin acts as an intercalator by binding to DNA, also inhibiting DNA and RNA synthesis. Both drugs have been shown to induce oxidative stress, 47, 48 suggesting an activation mechanism that may be similar to that seen after ionizing radiation. However, the Egr1 promoter can also be induced by agents that do not cause DNA damage and oxidative stress, such as resveratrol, vincristine and taxol. 21, 49 Whether CArG elements are responsible for drug-mediated activation is unknown, since the wild-type Egr1 promoter used in these studies contains putative binding sites for a number of transcription factors, such as Sp1, the Fos-Jun heterodimer Activator Protein 1 (AP1), cyclic AMP, Elk1 and Egr1 itself. 50 However, from the data presented here, it is possible to conclude that isolated CArG elements can be activated by cisplatin and doxorubicin, and efficiently control experimental gene therapy in human tumor cells. Moreover, cisplatin was shown to enhance HSVtk/GCV-induced cytotoxicity. This was somewhat surprising, as both cisplatin and activated GCV are mainly effective against cells in the S-phase of the cell cycle and require active DNA replication. 46, 51 Greater beneficial therapeutic effects may therefore be observed in highly proliferative breast cancer, which is characterized by negative long-term outcome after standard treatment. 52 Inducible promoters offer the potential to selectively control therapeutic gene expression in the tumor while minimizing normal tissue toxicity. Nevertheless, transgene expression is limited to the period of stimulation (e.g. radiotherapy treatment), returning to basal levels following withdrawal of the induction trigger. Consequently, we have also devised a ''molecular switch'' vector system based on Cre/loxP recombination, which allows longterm, high-level transgene expression following activation by a specific stimulus. 18 Furthermore, within the ''molecular switch'' context, promoters containing CArG elements are characterized by a particularly low basal, uninduced activity, 18 which would be particularly important after systemic, chemoactivation. Future work will therefore focus on the study of the therapeutic potential of combining chemotherapy, X-rays and neutron radiotherapy with CArG-mediated gene therapy strategies, especially within the ''molecular switch'' context.
